Treatment com AI Inc operates in the business of providing personalized health care information that is relevant and trustworthy empowering patients to make responsible, informed decisions about their health while improving communications, reducing costs and in-clinic wait times for medical practitioners.
2018
n/a
LTM Revenue n/a
LTM EBITDA n/a
$20.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Treatment | AI has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Treatment | AI achieved revenue of n/a and an EBITDA of -$2.5M.
Treatment | AI expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Treatment | AI valuation multiples based on analyst estimatesFY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | XXX |
Gross Profit | n/a | n/a | n/a | XXX | XXX |
Gross Margin | NaN% | NaN% | NaN% | XXX | XXX |
EBITDA | -$9.6M | -$2.6M | -$2.5M | n/a | XXX |
EBITDA Margin | -Infinity% | -Infinity% | -Infinity% | NaN% | XXX |
Net Profit | -$9.6M | -$2.6M | -$2.6M | XXX | XXX |
Net Margin | -Infinity% | -Infinity% | -Infinity% | XXX | XXX |
Net Debt | n/a | $0.4M | n/a | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 14, 2025, Treatment | AI's stock price is CAD 1 (or $0).
Treatment | AI has current market cap of CAD 29.4M (or $20.4M), and EV of CAD 29.3M (or $20.3M).
See Treatment | AI trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$20.3M | $20.4M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 14, 2025, Treatment | AI has market cap of $20.4M and EV of $20.3M.
Treatment | AI's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Treatment | AI's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Treatment | AI and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $20.3M | XXX | XXX | XXX |
EV/Revenue | n/a | XXX | XXX | XXX |
EV/EBITDA | n/a | XXX | XXX | XXX |
P/E | n/a | XXX | XXX | XXX |
P/E/Growth | n/a | XXX | XXX | XXX |
EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpTreatment | AI's NTM/LTM revenue growth is n/a
Treatment | AI's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Treatment | AI's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Treatment | AI's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Treatment | AI and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | n/a | XXX | XXX | XXX | XXX |
EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
EBITDA Growth | -3% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
Opex per Employee | n/a | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
Alcidion Group | XXX | XXX | XXX | XXX | XXX | XXX |
CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
Doctor Care Anywhere | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Treatment | AI acquired XXX companies to date.
Last acquisition by Treatment | AI was XXXXXXXX, XXXXX XXXXX XXXXXX . Treatment | AI acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was Treatment | AI founded? | Treatment | AI was founded in 2018. |
Where is Treatment | AI headquartered? | Treatment | AI is headquartered in Canada. |
Is Treatment | AI publicy listed? | Yes, Treatment | AI is a public company listed on CNQ. |
What is the stock symbol of Treatment | AI? | Treatment | AI trades under TRUE ticker. |
When did Treatment | AI go public? | Treatment | AI went public in 2021. |
Who are competitors of Treatment | AI? | Similar companies to Treatment | AI include e.g. Benevolent AI, Alcidion Group, CurveBeam AI, Doctor Care Anywhere. |
What is the current market cap of Treatment | AI? | Treatment | AI's current market cap is $20.4M |
Is Treatment | AI profitable? | Yes, Treatment | AI is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.